AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8362195 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan + 1.5% sodium lauryl sulfate (SLS)
Number of subjects: 11
Study 8362195 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% triclosan + 1.5% sodium lauryl sulfate (SLS)
Number of subjects: 11
Study 8362195 — intervention group
Group type: COMPARATOR
Intervention: 1.5% sodium lauryl sulfate (SLS)
Number of subjects: 11
Study 3318475 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol 0.5%-pilocarpine 2% twice a day
Number of subjects: 25
Study 3318475 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol 0.5%-pilocarpine 4% twice a day
Number of subjects: 25
Study 3318475 — intervention group
Group type: COMPARATOR
Intervention: pilocarpine 4% four times a day
Number of subjects: 25
Study 31217008 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook
Number of subjects: 2394
Study 31217008 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail
Number of subjects: 2394
Study 31217008 — intervention group
Group type: EXPERIMENTAL
Intervention: WhatsApp
Number of subjects: 2394
Study 31217008 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 2394
Study 29911355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemia treatment
Number of subjects: 0
Study 29911355 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcome
Number of subjects: 0
Study 27061162 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT)
Number of subjects: 18
Study 24647511 — intervention group
Group type: EXPERIMENTAL
Intervention: Four weeks of immobilization
Number of subjects: 100
Study 24647511 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight weeks of immobilization
Number of subjects: 100
Study 24647511 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 100
Study 23098680 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (0.5 mg, 2 mg, 6 mg, 12 mg)
Number of subjects: 146
Study 23098680 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 146
Study 23098680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 20647477 — intervention group
Group type: EXPERIMENTAL
Intervention: Particle-mediated epidermal delivery (PMED) with 4 microg mouse gp100 DNA
Number of subjects: 27
Study 20647477 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (i.m.) injection with 2,000 microg mouse gp100 DNA
Number of subjects: 27
Study 18704636 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m² on days 1, 8, and 15 of a 28-day cycle
Number of subjects: 28
Study 18704636 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m² (with dose reduction to 800 mg/m² in 5 patients due to toxicity)
Number of subjects: 28
Study 18704636 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m²
Number of subjects: 28
Study 15965168 — intervention group
Group type: COMPARATOR
Intervention: Classic laser treatment
Number of subjects: 24
Study 15965168 — intervention group
Group type: EXPERIMENTAL
Intervention: Light laser treatment
Number of subjects: 24
Study 14651353 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Radionuclide Cystography (DRNC)
Number of subjects: 25
Study 14651353 — intervention group
Group type: COMPARATOR
Intervention: Voiding Cystourethrography (VCUG)
Number of subjects: 25
Study 14651353 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DRNC and VCUG
Number of subjects: 25
Study 10557021 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (15mg/d)
Number of subjects: 32
Study 10557021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 8916634 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 97
Study 8916634 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse prevention therapy
Number of subjects: 97
Study 8916634 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 97
Study 8916634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 1679254 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous low dose antipsychotic medication
Number of subjects: 0
Study 1679254 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent or targeted medication
Number of subjects: 0
Study 1679254 — intervention group
Group type: COMPARATOR
Intervention: Established moderate dose antipsychotic medication
Number of subjects: 0
Study 6341252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefroxadine (1 g t.i.d. for five days)
Number of subjects: 0
Study 6341252 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin (1 g t.i.d. for five days)
Number of subjects: 0
Study 31113752 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 250 mg twice daily for 6 months
Number of subjects: 200
Study 31113752 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic treatment)
Number of subjects: 200
Study 27754790 — intervention group
Group type: EXPERIMENTAL
Intervention: Antireflux stent (ARS); n=6
Number of subjects: 13
Study 27754790 — intervention group
Group type: COMPARATOR
Intervention: Conventional plastic stent; n=7
Number of subjects: 13
Study 26797555 — intervention group
Group type: EXPERIMENTAL
Intervention: Noisy intraoperative environment
Number of subjects: 20
Study 26797555 — intervention group
Group type: COMPARATOR
Intervention: Quiet intraoperative environment
Number of subjects: 20
Study 24259653 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem 500 mg (1-hour infusion) every 8 hours
Number of subjects: 20
Study 24259653 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 1 g (0.5-hour infusion) every 8 hours
Number of subjects: 20
Study 22546317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozioma News Service
Number of subjects: 24
Study 22546317 — intervention group
Group type: COMPARATOR
Intervention: Control newspapers
Number of subjects: 24
Study 20131578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation
Number of subjects: 0
Study 20131578 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional rehabilitation
Number of subjects: 0
Study 17986324 — intervention group
Group type: EXPERIMENTAL
Intervention: Local injection of 20 ml Carbostesin 0.25% at the end of the operation
Number of subjects: 264
Study 17986324 — intervention group
Group type: COMPARATOR
Intervention: 20 ml placebo (0.9% Saline) injection
Number of subjects: 264
Study 15994611 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 101
Study 15994611 — intervention group
Group type: COMPARATOR
Intervention: Discharged home
Number of subjects: 101
Study 12668574 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir 800 mg every 8 h
Number of subjects: 36
Study 12668574 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir 800 mg + ritonavir 100 mg every 12 h
Number of subjects: 36
Study 10320251 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (0.5 microg x kg(‐1) x min(‐1))
Number of subjects: 22
Study 9604487 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeraz®
Number of subjects: 22
Study 9604487 — intervention group
Group type: COMPARATOR
Intervention: Losec®
Number of subjects: 22
Study 1866408 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP-therapy
Number of subjects: 21
Study 1866408 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 375-400 mg in the evening
Number of subjects: 21
Study 1866408 — intervention group
Group type: EXPERIMENTAL
Intervention: O2-therapy by 21/min, by nasal prongs
Number of subjects: 21
Study 6406165 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calorie and protein supplement
Number of subjects: 0
Study 6406165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31873856 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer screening program
Number of subjects: 318
Study 29186319 — intervention group
Group type: COMPARATOR
Intervention: i.v. carboplatin/paclitaxel
Number of subjects: 275
Study 29186319 — intervention group
Group type: EXPERIMENTAL
Intervention: i.p. carboplatin plus i.v./i.p. paclitaxel
Number of subjects: 275
Study 27657476 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose diuretics (HD)
Number of subjects: 96
Study 27657476 — intervention group
Group type: EXPERIMENTAL
Intervention: Low diuretic efficiency (DE)
Number of subjects: 96
Study 27657476 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration
Number of subjects: 96
Study 27657476 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening renal function (WRF)
Number of subjects: 96
Study 25689128 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 45
Study 25689128 — intervention group
Group type: EXPERIMENTAL
Intervention: Vesicoamniotic shunting (VAS)
Number of subjects: 45
Study 24312305 — intervention group
Group type: EXPERIMENTAL
Intervention: High-exposure group (antimicrobial treatment with piperacillin/tazobactam, meropenem, ciprofloxacin)
Number of subjects: 1147
Study 24312305 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC group, antimicrobial treatment with cefuroxime)
Number of subjects: 1147
Study 24312305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 1147
Study 24312305 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 1147
Study 20374604 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmetic regimen (n = 99): SPF 30 moisturizing lotion with 5% niacinamide, peptides, antioxidants; moisturizing cream with niacinamide and peptides; targeted wrinkle product with niacinamide, peptides, and 0.3% retinyl propionate
Number of subjects: 196
Study 20374604 — intervention group
Group type: COMPARATOR
Intervention: Prescription regimen (n = 97): 0.02% tretinoin plus moisturizing SPF 30 sunscreen
Number of subjects: 196
Study 18177635 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching events designed according to the explanation-based learning (EBL) account
Number of subjects: 0
Study 18177635 — intervention group
Group type: COMPARATOR
Intervention: Modified teaching events that removed one of the EBL steps
Number of subjects: 0
Study 17712656 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 1000 mg, twice daily
Number of subjects: 175
Study 17712656 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 500 mg, twice daily
Number of subjects: 175
Study 17712656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 12672536 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 13
Study 12672536 — intervention group
Group type: COMPARATOR
Intervention: Control-mixture ingestion
Number of subjects: 13
Study 10759664 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (1-2 mg daily, 0.5 mg twice daily for 2 weeks, then 1 mg twice daily for 2 weeks)
Number of subjects: 61
Study 10759664 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (0.2 mg daily for 4 weeks)
Number of subjects: 61
Study 8997678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg 1 hour presurgery and 400 mg postsurgery)
Number of subjects: 9
Study 8997678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1310584 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/Carbidopa
Number of subjects: 7
Study 6403962 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital 200 mg
Number of subjects: 5
Study 6403962 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital 400 mg
Number of subjects: 5
Study 6403962 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital 600 mg
Number of subjects: 5
Study 6403962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 30264977 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (100 mg/day for 4 weeks)
Number of subjects: 20
Study 30264977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29543133 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Aerobic Exercise (AE) - 40 min of cycling at ∼70% maximal HR
Number of subjects: 6
Study 29543133 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Resistance Exercise (RE) - 8 sets, 10 reps at ∼65% 1-repetition maximum (1RM)
Number of subjects: 6
Study 27707836 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week resistance training
Number of subjects: 60
Study 27707836 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 60
Study 24621109 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF 200/12 μg twice daily
Number of subjects: 419
Study 24621109 — intervention group
Group type: COMPARATOR
Intervention: FP/S 500/50 μg twice daily
Number of subjects: 419
Study 21933347 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian approach for lithium drug monitoring
Number of subjects: 97
Study 21933347 — intervention group
Group type: COMPARATOR
Intervention: Traditional steady-state blood sampling
Number of subjects: 97
Study 19357404 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice a day
Number of subjects: 412
Study 19357404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study 18080349 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidform
Number of subjects: 81
Study 18080349 — intervention group
Group type: EXPERIMENTAL
Intervention: BufferGel
Number of subjects: 81
Study 18080349 — intervention group
Group type: COMPARATOR
Intervention: KY Jelly
Number of subjects: 81
Study 15191772 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 3044
Study 15191772 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 3044
Study 15191772 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoglobin as a continuous variable
Number of subjects: 3044
Study 15191772 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoglobin sub-divided by 1.0 g/dL increments
Number of subjects: 3044
Study 15191772 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaemic and polycythaemic patients
Number of subjects: 3044
Study 11589263 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen lysine salt (KLS) mouthwash (10 mL diluted in 100 mL of water, gargled twice daily for up to 7 days)
Number of subjects: 241
Study 11589263 — intervention group
Group type: COMPARATOR
Intervention: Benzydamine hydrochloride (BH) mouthwash (15 mL, 22.5 mg, gargled twice daily for up to 7 days)
Number of subjects: 241
Study 9647140 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 30
Study 9647140 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 30
Study 7801606 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant agitation
Number of subjects: 0
Study 7801606 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual mixing once every 24 h
Number of subjects: 0
Study 7801606 — intervention group
Group type: COMPARATOR
Intervention: No agitation
Number of subjects: 0
Study 2686744 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 100 mg once daily (6 months to 5 years), 200 mg once daily (5 to 10 years), 300 mg once daily (10 to 16 years)
Number of subjects: 325
Study 2686744 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin 62.5 mg tds (6 months to 1 year), 125 mg tds (1 to 7 years), 250 mg tds (7 to 16 years)
Number of subjects: 325
Study 2686744 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 325
Study 2686744 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 325
Study 810295 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (P)
Number of subjects: 20
Study 810295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30572072 — intervention group
Group type: EXPERIMENTAL
Intervention: Exception from informed consent (EFIC) implementation strategies including community consultation (CC) and public disclosure (PD) methods.
Number of subjects: 0
Study 30572072 — intervention group
Group type: EXPERIMENTAL
Intervention: Community consultation (CC) methods such as social media advertising, random digit dialing surveys, working with city officials, and websites with embedded surveys.
Number of subjects: 0
Study 30572072 — intervention group
Group type: EXPERIMENTAL
Intervention: Public Disclosure activities including press releases, website documentation, and letters to community members and local officials.
Number of subjects: 0
Study 30572072 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from community consultation (CC) to study approval.
Number of subjects: 0
Study 28433995 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic dialysis (3 times prior to surgery)
Number of subjects: 88
Study 28433995 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dialysis)
Number of subjects: 88
Study 25480462 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 60
Study 25480462 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 60
Study 25480462 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram and Nortriptyline
Number of subjects: 60
Study 24341820 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) guided antibiotic therapy
Number of subjects: 225
Study 24341820 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with antibiotics at physician's discretion (Control)
Number of subjects: 225
Study 21488594 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with fluorouracil and folinic acid (de Gramont protocol)
Number of subjects: 3000
Study 21488594 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of oxaliplatin to fluorouracil + folinic acid (Folfox 4 protocol)
Number of subjects: 3000
Study 21488594 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of irinotecan to fluorouracil + folinic acid
Number of subjects: 3000
Study 21488594 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil precursors (capecitabine and tegafur)
Number of subjects: 3000
Study 21488594 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Number of subjects: 3000
Study 21488594 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for stage II disease
Number of subjects: 3000
Study 19733054 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner present during neuraxial anesthesia placement
Number of subjects: 315
Study 19733054 — intervention group
Group type: COMPARATOR
Intervention: Partner not present during neuraxial anesthesia placement
Number of subjects: 315
Study 19733054 — intervention group
Group type: COMPARATOR
Intervention: Partner not present
Number of subjects: 315
Study 17978999 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 374
Study 17978999 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Number of subjects: 374
Study 17978999 — intervention group
Group type: EXPERIMENTAL
Intervention: HINT1 TT genotype
Number of subjects: 374
Study 17978999 — intervention group
Group type: EXPERIMENTAL
Intervention: ARRB2 and OPRM1 genotype interaction
Number of subjects: 374
Study 15156311 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemetacin (ACE) 90 mg bid for 6 weeks
Number of subjects: 105
Study 15156311 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib (CEL) 200 mg bid for 6 weeks
Number of subjects: 105
Study 15156311 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemetacin (ACE)
Number of subjects: 105
Study 15156311 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib (CEL)
Number of subjects: 105
Study 11410698 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) over the abdomen and posterior back muscles in addition to physical therapy for 6 weeks
Number of subjects: 2
Study 11410698 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only physical therapy for 6 weeks
Number of subjects: 2
Study 11410698 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) group
Number of subjects: 2
Study 9579280 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tacrine treatment
Number of subjects: 16
Study 8053616 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (3 million units) three times a week subcutaneously for 4 weeks
Number of subjects: 15
Study 8053616 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Number of subjects: 15
Study 8053616 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mL saline)
Number of subjects: 15
Study 2789364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponsinomycin 800 mg syrup administered during a standard meal
Number of subjects: 12
Study 2789364 — intervention group
Group type: COMPARATOR
Intervention: Ponsinomycin 800 mg syrup administered 2 hours before a standard meal
Number of subjects: 12
Study 31394945 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational Emotive Behavior Therapy (REBT)
Number of subjects: 30
Study 31394945 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 31724346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongdu Tiaoshen acupuncture method
Number of subjects: 96
Study 31724346 — intervention group
Group type: COMPARATOR
Intervention: Non-penetrating sham acupuncture
Number of subjects: 96
Study 31724346 — intervention group
Group type: EXPERIMENTAL
Intervention: Health guidance (waiting group)
Number of subjects: 96
Study 28426106 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/day
Number of subjects: 226
Study 28426106 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib 250 mg/day
Number of subjects: 226
Study 28426106 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (exon 19 deletion)
Number of subjects: 226
Study 28426106 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib (exon 19 deletion)
Number of subjects: 226
Study 28426106 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (L858R)
Number of subjects: 226
Study 28426106 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib (L858R)
Number of subjects: 226
Study 25654365 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-grade IVH (grades I-II)
Number of subjects: 462
Study 25654365 — intervention group
Group type: COMPARATOR
Intervention: No low-grade IVH (grades I-II)
Number of subjects: 462